Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management
Author(s) -
Luigi Di Biase,
J. David Burkhardt,
Pasquale Santangeli,
Prasant Mohanty,
Javier Sánchez,
Rodney Horton,
G. Joseph Gallinghouse,
Sakis Themistoclakis,
Antonio Rossillo,
Dhanunjaya Lakkireddy,
Madhu Reddy,
Steven Hao,
Richard Hongo,
Salwa Beheiry,
Jason Zagrodzky,
Rong Bai,
Sanghamitra Mohanty,
Claude S. Elayi,
Giovanni B. Forleo,
Gemma Pelargonio,
Maria Lucia Narducci,
Antonio Dello Russo,
Michela Casella,
Gaetano Fassini,
Claudio Tondo,
Robert A. Schweikert,
Andrea Natale
Publication year - 2014
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.113.006426
Subject(s) - medicine , warfarin , atrial fibrillation , discontinuation , catheter ablation , cardiology , odds ratio , stroke (engine) , randomized controlled trial , ablation , confidence interval , clinical endpoint , incidence (geometry) , surgery , anesthesia , mechanical engineering , physics , optics , engineering
Periprocedural thromboembolic and hemorrhagic events are worrisome complications of catheter ablation for atrial fibrillation (AF). The periprocedural anticoagulation management could play a role in the incidence of these complications. Although ablation procedures performed without warfarin discontinuation seem to be associated with lower thromboembolic risk, no randomized study exists.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom